Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers

Valbenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for tardive dyskinesia treatment by the US Food and Drug Administration; its major active metabolite (NBI‐98782) is a 45‐fold more potent inhibitor of VMAT2 than the parent drug. This study aimed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Woo Kyung, Hwang, Inyoung, Kim, Byungwook, Jung, Jihyun, Yu, Kyung‐Sang, Jang, In‐Jin, Oh, Jaeseong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014685/
https://www.ncbi.nlm.nih.gov/pubmed/36514192
http://dx.doi.org/10.1111/cts.13466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014685/
https://www.ncbi.nlm.nih.gov/pubmed/36514192
http://dx.doi.org/10.1111/cts.13466

Ejemplares similares